10. Zoll Medical (ZOLL)
Company profile: Zoll, with a market value of $2 billion, makes medical equipment used to resuscitate victims of trauma or cardiac arrest.
Investor takeaway: Its shares are up 19% this year and 53% over the past three months, and have a three-year, average annual return of 88%.
Analysts give its shares four "buy" ratings, three "buy/holds," and one "hold," according to a survey of analysts by S&P.Revenue has risen steadily over the past five years and, earnings, over three years. For fiscal 2012, analysts estimate Zoll Medical will earn $1.95 per share and that will grow by 36% to $2.65 in 2013. 9. Ista Pharmaceuticals (ISTA) Company profile: Ista Pharmaceuticals, with a market value of $355 million, develops various drugs for the ophthalmic market. It is also working on allergy drugs. Investor takeaway: Ista's shares are up 21% this year, including 116% in the past three months, and have a three-year, average annual return of 69%. Analysts give the stock one "buy/hold" rating and three "holds," per S&P. For fiscal 2012, analysts estimate earnings will grow 312% to 33 cents per share. For 2011, the company reported a net loss of $57 million or $1.47 per share, but it had operating income of $2.28 per share. 8. Buffalo Wild Wings (BWLD) Company profile: Buffalo Wild Wings, with a market value of $1.6 billion, is a casual dining restaurant chain that owns and franchises 560 restaurants in 38 states. Investor takeaway: Buffalo Wild Wings' shares are up 32% this year, 42% over the past three months, and have a three-year, average annual return of 43%. Analysts give them seven "buy" ratings, one "buy/holds," nine "holds," and one "sell," according to S&P. Analysts estimate it will earn $3.28 per share this year and that that will grow by 17% to $3.85 in 2013. Revenue, earnings and cash flow are up by double-digit amounts over the past five years. 7. Mako Surgical (MAKO) Company profile: Mako Surgical, with a market value of $1.6 billion, develops a robotic device and implants for a minimally invasive knee procedure called the MAKOplasty. Investor takeaway: Its shares are up 41% over the past three months and have a three-year average annual return of 77%. Analysts give them one "buy" rating, two "buy/holds," and five "holds," according to S&P. 6. Bio-Reference Labs (BRLI) Company profile: Bio-Reference Labs, with a market value of $642 million, is a New Jersey-based company that performs chemical-diagnostic tests, including blood and urine analysis, hematology services, pap smears and other types of tests. Investor takeaway: Its shares are up 42% this year, including 65% in the past three months, and have a three-year, average annual return of 29%. Analysts give the stock three "buy" ratings and two "holds," according to a survey of analysts by S&P. Bio-Reference Labs expected to earn $1.45 per share this year, and that that will grow by 19% to $1.73 per share in 2013. The company has five years of steady revenue, earnings and cash flow growth.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV